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patients identified by the neonatal screening and treated earlier 
than historical patients showed improved outcome in terms of 
motor activity and ventilatory-free survival.
The immune status of PD patients has emerged as another 
important factor that impacts ERT efficacy. In a recent study 
the effects of ERT in 11 cross-reactive immunological material 
(CRIM) negative patients were compared with those obtained in 
21 CRIM positive patients (7). CRIM-positive patients showed 
lower antibody titers, and a better response to ERT, while CRIM-
negative patients showed an attenuated response to enzyme with 
significantly decreased survival, invasive ventilation-free sur-
vival, less improvement in cardiac response, and regression of 
motor milestones.
Other studies implicated cellular abnormalities triggered 
by glycogen storage as additional factors affecting ERT effica-
cy. Cardone et al. (8) demonstrated an abnormal recycling of the 
cation-independent  mannose-6-phosphate  receptor  (CI-MPR) 
in cultured PD fibroblasts. As the integrity of the CI-MPR path-
way is essential for efficient uptake and lysosomal delivery of 
recombinant enzymes used for ERT, the abnormal trafficking of 
the receptor in PD fibroblasts resulted in an impaired correction 
of enzyme activity by rhGAA. The abnormalities of CI-MPR 
trafficking were more prominent in fibroblasts from severe and 
intermediate PD patients, apparently correlating with disease 
severity. 
Raben  et  al.  (9)  demonstrated  that  abnormalities  of  au-
tophagy also impact on ERT efficacy and that suppression of 
autophagy in combination with ERT resulted in a near-complete 
glycogen clearance and restoration of skeletal muscle architec-
ture in a mouse model of PD.
The limitations of ERT efficacy point to the need for im-
proved therapeutic strategies such as immune modulation, early 
start of ERT, pharmacological chaperone therapy (10) and its 
combination  with  ERT  (11),  substrate  reduction  (12).  Gene 
therapy is currently under investigation as an alternative thera-
peutic option for the treatment of PD patients.
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Until the end of the last century the management of Pompe 
disease  (PD)  was  exclusively  based  on  multidisciplinary  in-
terventions aimed at providing support therapies to patients. 
Enzyme replacement therapy (ERT) with recombinant human 
GAA (rhGAA, Myozyme) was introduced in 2000 and is pres-
ently the only approved pharmacological treatment for PD. rh-
GAA is administered periodically to patients by an intravenous 
route, and is internalized by cells and target tissues through the 
mannose-6-phosphate receptor pathway.
The  first  clinical  study  on  ERT  in  PD  was  conducted 
in four Dutch patients affected by the infantile form of the 
disease (1) that were treated for 36 weeks with an enzyme 
preparation derived from transgenic rabbit milk. Both the re-
sults of this trial and those of a long-term follow-up study (2) 
supported the efficacy of ERT on cardiac involvement, motor 
activity, and patients’ survival. Since then a number of reports 
of almost a hundred patients treated with rhGAA, mostly with 
the classical infantile-onset PD, were published in the litera-
ture. Recently formal studies on the efficacy of ERT in PD 
were performed also in patients with the juvenile/adult forms 
of the disease (3, 4). An international PD registry has become 
active since 2004, and will likely add further information on 
long-term efficacy of ERT.
Like  for  other  lysosomal  storage  diseases  ERT  in  PD 
showed  important  success  together  with  some  limitations. 
Specifically, excellent results were obtained in terms of func-
tional correction of cardiac disease and of glycogen clearance 
in liver. On the other hand it became evident that correction of 
skeletal muscle pathology is a difficult challenge and that not 
all patients respond equally to ERT (5). Several factors appear 
to affect the efficacy of ERT and the outcome of PD patients, 
including age at the start of treatment, stage of skeletal muscle 
damage, antibody responses, insufficient targeting of rhGAA 
to skeletal muscle and high clearance of the enzyme by the 
liver.
It was a common experience of physicians involved in the 
care of PD patients that the earlier was start of treatment, the 
better would be the outcome. This concept was formally proven 
by recent studies done in Taiwan, where a large-scale newborn 
screening  pilot  program  was  performed  during  the  past  few 
years (6). The results from this study clearly indicated that in 206
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were later transitioned to CHO-derived enzyme (Myozyme). 
Weekly infusions of 10 mg/kg resulted in an only slight increase 
of muscle GAA activity. After 12 to 24 weeks of therapy the 
ERT dosage was increased to 20 mg/kg weekly. At baseline, 
all  patients  were  wheelchair-bound  and  the  2  older  patients 
needed ventilatory support; after 72 weeks of treatment all pa-
tients showed stabilized pulmonary function, were less fatigued 
whereas laboratory tests revealed a decrease of creatine kinase, 
transaminases and LDH levels. The distal muscles responded 
better than the proximal ones. The best clinical response was 
observed in the youngest patient, who was less affected when 
he began therapy. The stabilization of pulmonary and muscle 
function as well as the improvement in quality of life during the 
first 3 years of therapy were maintained throughout the 5 year 
extension period (1).
An observational, open-label, follow-up study of 3 juve-
nile  Pompe  patients  presenting  without  cardiomyopathy  has 
been reported in 2010. Those three patients received ERT with 
three different protocols with dosages ranging from 10-40 mg/
kg every other week. The less affected patient (3 years and 8 
months at start) showed a significant improvement of muscle 
function with no regression during 70 weeks of follow-up. The 
second patient (2 years and 8 months at start) initially showed 
improved muscle functions, motor skills, and development, but 
he reached a plateau around week 114 despite an increased dose 
during the following 35 weeks. The third patient (19 years and 9 
months at start) had severe skeletal muscle condition at baseline 
and died suddenly after only 20 weeks of ERT (2).
An open label trial of ERT was conducted in 44 late-onset 
GSD II patients with variable disease severity. Alglucosidase 
alfa was administred at the standard dose (20 mg/kg every other 
week). Clinical assessments included serial arm function tests 
(AFT), Walton Gardner Medwin scale (WGMS), timed 10-m 
walk tests, four-stair climb tests, modified Gowers’ maneuvers, 
6-min walk test (6MWT), MRC sum score, forced vital capac-
ity (FVC), creatine kinase (CK) levels and SF-36 self-reporting 
questionnaires. After  12  months  of  ERT,  the  authors  found 
significant  changes  of  the  modified  Gowers’  maneuvers,  the 
6-min walk test and the CK levels, while all other tests were 
unchanged. No serious adverse events occurred and none of the 
patients died or required de novo ventilation (3).
The  first  randomized,  double-blind,  placebo-controlled 
phase III study in late onset GSD II (LOTS) enrolled, in the 
United States and Europe, 90 patients ambulatory and free of 
invasive ventilation. They were randomly assigned to receive 
biweekly, for 78 weeks,.i.v. alglucosidase alfa at standard doses 
or placebo. Study primary endpoints were the evaluations of 
6MWT and the pulmonary function. After that treatment the pa-
tients showed an improved walking distance and stabilization of 
pulmonary function (4).
Most recently, Angelini et al. studied the efficacy of ERT in 
a large cohort of Italian patients treated from 12 months up to 54 
months. While the LOTS study included only walking and non-
ventilated patients, they enrolled also severely affected patients 
with assisted ventilation (36%) or confined to wheelchair (10%). 
They observed an improvement of motor functions which per-
sisted in time as demonstrated by the group of patients treated for 
over 36 months. Six patients discontinued ventilation and 22 cas-
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Introduction 
Pompe disease also known as glycogen storage disease type 
II (GSD type II) is a lysosomal disorder due to alfa-glucosidase 
deficiency, a key enzyme in glycogen degradation. The juve-
nile and adult forms, considered late-onset GSDII, are mainly 
characterized by slowly progressive muscle disorders mimick-
ing limb-girdle dystrophies or inflammatory myopathies, and 
or by respiratory involvement with diaphragmatic paralysis and 
restrictive respiratory insufficiency.
The histopathological hallmark is revealed by increased 
muscle fiber vacuolization with vacuoles filled of PAS-positive 
material and by strong reaction for lysosomal acid phosphatase. 
The degree of vacuolization is extremely variable in late-onset 
patients, and seems independent from age of onset, disease du-
ration, or clinical features. 
In the last few years, major advances in this field have 
been represented by the development and manufacturing of re-
combinant human GAA (rhGAA) produced and purified from 
Chinese hamster ovary cells (CHO) for enzyme replacement 
therapy (ERT). 
Clinical trials of ERT in late-onset patients 
In 2006 human acid α-glucosidase (alglucosidase alfa, My-
ozyme, Genzyme Corporation, Framingham, MA) has received 
broad-label marketing approval in Europe and, later, in the U.S. 
This type of treatment has already been applied to other lyso-
somal disorders but it represents the first attempt of targeting 
recombinant enzyme to skeletal muscle. 
Although it has been demostrated that ERT is effective in 
infantile  form,  improving  respiratory  failure  and  prolonging 
children’s survival, informations on ERT efficacy in late-onset 
GSDII forms remain still limited. 
In 2004, Winkel et al reported a 3-year follow-up study for 
3 late-onset patients (aged 11, 16, and 32 years). Those patients 
started therapy with rhGAA from milk of transgenic rabbits, but 